Table 1 Overview of the clinical development of Cu-modulating agents
From: Copper homeostasis and cuproptosis in health and disease
Agents | Action | Indication and testing stage | Ref(s) |
|---|---|---|---|
D-penicillamine | Chelator | Wilson’s disease (approved) | |
Tetrathiomolybdate | Chelator | Wilson’s disease (phase II) | |
Trientine | Chelator | Wilson’s disease (approved) | |
WTX101 | Chelator | Wilson’s disease (phase III) | |
Clioquinol | Ionophore | Fungal infection (approved) | |
CuII(atsm) | Ionophore | Amyotrophic lateral sclerosis (phase II) | |
Disulfiram | Ionophore | Glioblastoma (phase I/II) | |
Elesclomol | Ionophore | Melanoma (phase III) |
